MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 14, 2008; DOI: 10.1124/mol.108.049718


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.108.049718v1
74/5/1453    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by De Arcangelis, V.
Right arrow Articles by Xiang, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Arcangelis, V.
Right arrow Articles by Xiang, Y.


Received for publication June 17, 2008.
Revised August 11, 2008.
Accepted for publication August 13, 2008.

Phosphodieasterase 4 and phosphatase 2A differentially regulate cAMP/PKA signaling for cardiac myocyte contraction under stimulation of {beta}1 adrenergic receptor

Vania De Arcangelis 1, Dagoberto Soto 1, Yang Xiang 1*

1 University of Illinois at Urbana-Champaign

* Address correspondence to: E-mail: kevinyx{at}life.uiuc.edu

Abstract

Activation of {beta} adrenergic receptor (AR) induces a tightly controlled cAMP/PKA activity to ensure an agonist dose-dependent and saturable contraction response in animal heart. We have found that stimulation of {beta}1AR by isoproterenol induces maximal contraction responses at the dose of 10-6 M in cardiac myocytes, however cAMP accumulaton continues to increase with higher agonist concentrations. Dose dependent cAMP accumulation is tightly controlled by negative regulator phosphodiesterase 4 (PDE4) that hydrolyzes cAMP. At 10-9 M isoproterenol, cAMP accumulation is minimal due to the hydrolysis of cAMP by PDE4, which leads to small increase in PKA phosphorylation of phospholamban and troponin I (TnI), and contraction responses. Inhibition of PDE4 activity with rolipram enhances cAMP accumulation, yields maximal PKA phosphorylation of phospholamban and TnI, and myocyte contraction responses. In contrast, at 10-5 M isoproterenol, despite the negative effect of PDE4, cAMP accumulation is sufficient for maximal PKA phosphorylation of phospholamban and TnI. Inhibition of PDE4 with rolipram enhances cAMP accumulation, but not PKA phosphorylation and contraction responses. Interestingly, activities of both PKA and phosphatase 2A (PP2A) are enhanced under {beta}1AR activation with 10-5 M isoproterenol, and PP2A is recruited to PKA/AKAP complex. Inhibition of PP2A with okadaic acid further enhances the phosphorylation of phospholamban and TnI as well as contraction responses induced by 10-5 M isoproterenol. Therefore, PP2A plays a key role to limit PKA phosphorylation of phospholamban and TnI for myocyte contraction responses under {beta}1AR stimulation.


Key words: Adrenergic, Adenylyl cyclases, cAMP, Phosphodiesterases, Protein Kinase A, Protein ser/thr Phosphatases, Phosphorylation/Dephosphorylation





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics